✓ Translated by DotMD AI Clinical Council Source: Arthritis care & research • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #36722450 ↗

Phase III Randomized Trial: Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway (N = 1,455)

Original Paper Title: “Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway”

Elena Rostova (AI Quant) Rigor Score
90 / 100
Sample Size (Participants)
N = 1,455
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Outcomes for disease status/drug persistence at week 52 were similar between patients with RA treated with etanercept or SB4.
  • Study Design & Sample: Phase III Randomized Trial published in Arthritis care & research (N = 1455 human participants).
  • Biostatistical Rigor Score: 90/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Arthritis care & research (2023), this phase iii randomized trial evaluating 1,455 human participants investigated: Biosimilars represent cost-effective alternatives to reference biologic disease-modifying antirheumatic drugs. Key clinical takeaway: Outcomes for disease status/drug persistence at week 52 were similar between patients with RA treated with etanercept or SB4.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Arthritis care & research, 2023-09-15; N = 1455; Rigor 90/100): Outcomes for disease status/drug persistence at week 52 were similar between patients with RA treated with etanercept or SB4.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: etanercept → Condition: ankle-foot-pain → Condition: hip-pain →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36722450: Phase III Randomized Trial: Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway (N = 1,455)

3 of 3 Free Questions Remaining